Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05071209 · ClinicalTrials.gov registry record · Phase 1
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
A Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 20
- Study locations
NCT05071209 is a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05071209, a Phase 1 study of Refractory Malignant Solid Neoplasm and Refractory Lymphoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- DRUG Elimusertib
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- UCSF Medical Center-Mission Bay - San Francisco
Missouri
- Children's Mercy Hospitals and Clinics - Kansas City
- Washington University School of Medicine - St Louis
New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Alabama
- Children's Hospital of Alabama - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Johns Hopkins All Children's Hospital - St. Petersburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-12-22 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05071209
The ClinicalTrials.gov registry entry for NCT05071209 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 64-participant average among 59 other Refractory Malignant Solid Neoplasm trials with a reported enrollment target (52% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Refractory Malignant Solid Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Elimusertib is the first listed.
NCT05071209 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT05071209 about?
NCT05071209 is a clinical study titled "Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors". This phase I/II trial tests the safety, best dose, and whether elimusertib works in treating patients with solid tumors that have come back (relapsed) or does not respond to treatment (refractory). Elimusertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT05071209?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2021-12-22. Estimated completion is 2026-03-31.
What conditions does trial NCT05071209 study?
This clinical trial studies the following conditions: Refractory Malignant Solid Neoplasm, Refractory Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Ewing Sarcoma, Recurrent Lymphoma.
What interventions are being tested in trial NCT05071209?
The interventions under investigation include: Elimusertib (DRUG).
Who is sponsoring clinical trial NCT05071209?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05071209 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Studying TAK-243 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
RECRUITING · Phase 1
-
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
RECRUITING · Phase 1
-
AOH1996 for the Treatment of Refractory Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.